Evaluation of BCL2 and BIM Expression and KRAS Mutations in Lung Adenocarcinoma

被引：0
|
作者：
Chi, A. W. [1 ]
Johnstone, S. E. [1 ]
Heist, R. [1 ]
Mark, E. [1 ]
Mino-Kenudson, M. [1 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
MODERN PATHOLOGY | 2014年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1951
引用
收藏
页码：475A / 475A
页数：1
相关论文
共 50 条
  • [41] An investigation of the role of a promotor polymorphism in the BCL2 gene in BCL2 protein expression and survival from breast cancer
    Searle, Claire
    Brock, I.
    Cross, S.
    Cox, A.
    JOURNAL OF MEDICAL GENETICS, 2010, 47 : S118 - S118
  • [42] Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation
    Schraders, M
    de Jong, D
    Kluin, P
    Groenen, PC
    van Krieken, H
    JOURNAL OF PATHOLOGY, 2005, 205 (03): : 329 - 335
  • [43] BCL2 IS SYNTHETIC LETHAL TO IDH1/2 MUTATIONS IN AML
    不详
    CANCER DISCOVERY, 2015, 5 (03) : 223 - 223
  • [44] Functional Cooperation of the Proapoptotic Bcl2 Family Proteins Bmf and Bim In Vivo
    Huebner, Anette
    Cavanagh-Kyros, Julie
    Rincon, Mercedes
    Flavell, Richard A.
    Davis, Roger J.
    MOLECULAR AND CELLULAR BIOLOGY, 2010, 30 (01) : 98 - 105
  • [45] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Luka Brcic
    Marko Jakopovic
    Marija Misic
    Fran Seiwerth
    Izidor Kern
    Silvana Smojver-Jezek
    Franz Quehenberger
    Miroslav Samarzija
    Sven Seiwerth
    Diagnostic Pathology, 11
  • [46] Landscape and Functional Significance of KRAS Co-Mutations in Lung Adenocarcinoma (LUAC)
    Skoulidis, Ferdinandos
    Byers, Lauren
    Tong, Pan
    Diao, Lixia
    Denning, Warren
    Gudikote, Jayanthi
    Fan, Youhong
    Papadimitrakopoulou, Vassiliki
    Izzo, Julie G.
    Behrens, Carmen
    Kadara, Humam
    Cuentas, Edwin R. Parra
    Rodriguez-Canales, Jaime
    Gibbons, Don L.
    Weinstein, John N.
    Girard, Luc
    Minna, John
    Wang, Jing
    Wistuba, IgnacioI.
    Heymach, John V.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S214 - S215
  • [47] Efficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11
    Krzyzanowska, Natalia
    Krawczyk, Pawel
    Chmielewska, Izabela
    Jankowski, Tomasz
    Wojas-Krawczyk, Kamila
    Milanowski, Janusz
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (03): : 197 - 202
  • [48] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Brcic, Luka
    Jakopovic, Marko
    Misic, Marija
    Seiwerth, Fran
    Kern, Izidor
    Smojver-Jezek, Silvana
    Quehenberger, Franz
    Samarzija, Miroslav
    Seiwerth, Sven
    DIAGNOSTIC PATHOLOGY, 2016, 11 : 1
  • [49] Concurrent EGFR and KRAS Mutations in Lung Adenocarcinoma: A Single Institution Case Series
    Schwartz, C.
    Khan, M.
    Nguyen, R.
    Pasquinelli, M.
    Feldman, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S600 - S601
  • [50] Coexistence of two missense mutations in the KRAS gene in adenocarcinoma of the lung; a case report
    Elshiekh, M.
    Arora, I.
    Du Parcq, P.
    Rieu, R.
    Gupta, N.
    Desai, S.
    Khorashad, J.
    Naresh, K.
    Viola, P.
    VIRCHOWS ARCHIV, 2018, 473 : S115 - S115
12345